| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5874104 | ASTELLAS | Treatment of systemic fungal infections with phospholipid particles encapsulating polyene antibiotics |
Feb, 2016
(8 years ago) | |
| US5965156 | ASTELLAS | Amphotericin B liposome preparation |
Oct, 2016
(7 years ago) | |
Ambisome is owned by Astellas.
Ambisome contains Amphotericin B.
Ambisome has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Ambisome are:
- US5874104
- US5965156
Ambisome was authorised for market use on 11 August, 1997.
Ambisome is available in injectable, liposomal;injection dosage forms.
Ambisome can be used as for the treatment of fungal infections.
The generics of Ambisome are possible to be released after 12 October, 2016.
Drugs and Companies using AMPHOTERICIN B ingredient
Market Authorisation Date: 11 August, 1997
Treatment: For the treatment of fungal infections
Dosage: INJECTABLE, LIPOSOMAL;INJECTION
More Information on Dosage
AMBISOME family patents
